Pengcheng Duan

Mr. Pengcheng Duan


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
SCShihan Chen
Shihan Chen
XWXingyu Wang
Xingyu Wang
JDJiaxing D ou
Jiaxing D ou
JWJiahui Wang
Jiahui Wang
LPLi xiao Pu
Li xiao Pu
FXFeng Xue
Feng Xue
Research on gut microbiota in Alzheimer’s disease (AD) has progressed from observational correlation studies toward investigation of causal relationships in preclinical models. Human observational studies have reported associations between alterations in gut microbiota and the entire spectrum of AD, from the preclinical stage to dementia, and are associated with Amyloid-beta (Aβ) deposition, phosphorylated Tau (p-tau) positivity, dysregulation of bile acid and short-chain fatty acid (SCFA) metabolism, as well as impaired intestinal barrier function. The strongest causal evidence currently derives from germ-free or antibiotic-treated animal models, fecal microbiota transplantation (FMT) between healthy controls and AD patients, and colonization by specific bacterial strains or metabolites—interventions that have been shown to modulate Aβ load, tau phosphorylation, microglial activation, synaptic pruning, and cognitive behavior in animal models. Mechanistically, the gut–brain axis in AD has been proposed to integrate four interconnected pathways, with the strength of evidence and the extent of human validation varying considerably across them: (1) reduced production of SCFA-producing bacteria accompanied by upregulation of pro-inflammatory pathways; (2) disruption of intestinal epithelial tight junctions, allowing lipopolysaccharide (LPS) and bacterial toxins to enter the systemic circulation; (3) reprogramming of peripheral and central innate immune systems, leading to hyperactivation of microglia and complement-mediated synaptic clearance; and (4) global rearrangement of microbial metabolite networks (including SCFAs, bile acids, tryptophan metabolites, and LPS), has been proposed to collectively regulate Aβ homeostasis, tau pathology, microglial activation, and blood–brain barrier (BBB) integrity. Clinically, the evidence base remains uneven: probiotics have been associated with some improvements in some inflammatory markers and cognitive measures in small randomized controlled trials (RCTs); FMT has been reported in case studies in human AD; modified ketogenic diets have been associated with cerebrospinal fluid (CSF) biomarkers; and molecules such as GV-971 (Sodium Oligomannate) provide proof-of-concept for microbiota-targeted strategies, though independent validation is needed. Overall, gut microbiota research in AD has advanced considerably, with animal and human studies suggesting that dysbiosis may contribute to AD pathology through immune, metabolic, and barrier-related pathways, although clinical intervention evidence remains preliminary and requires further validation.

30 July 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
SCShihan Chen
Shihan Chen
XWXingyu Wang
Xingyu Wang
JDJiaxing D ou
Jiaxing D ou
JWJiahui Wang
Jiahui Wang
LPLi xiao Pu
Li xiao Pu
FXFeng Xue
Feng Xue
Research on gut microbiota in Alzheimer’s disease (AD) has progressed from observational correlations to the validation of causal relationships. Human studies consistently demonstrate that alterations in gut microbiota span the entire spectrum of AD, from the preclinical stage to dementia, and are associated with Amyloid-beta (Aβ) deposition, phosphorylated Tau (p-tau) positivity, dysregulation of bile acid and short-chain fatty acid (SCFA) metabolism, as well as impaired intestinal barrier function. The strongest causal evidence comes from germ-free/antibiotic-treated animal models, fecal microbiota transplantation (FMT) between healthy controls and AD patients, and colonization by specific pathogenic bacteria or metabolites—interventions that directly modulate Aβ load, tau phosphorylation, microglial activation, synaptic pruning, and cognitive behavior. Mechanistically, the gut-brain axis in AD integrates four interconnected pathways: (1) reduced production of SCFA-producing acidogenic bacteria accompanied by upregulation of pro-inflammatory pathways; (2) disruption of intestinal epithelial tight junctions, allowing lipopolysaccharide (LPS) and bacterial toxins to enter the systemic circulation; (3) reprogramming of peripheral and central innate immune systems, leading to hyperactivation of microglia and complement-mediated synaptic clearance; and (4) global rearrangement of microbial metabolite networks (including SCFAs, bile acids, tryptophan-ketouric acid derivatives, and LPS), collectively regulating Aβ homeostasis, tau pathology, microglial activation, and blood-brain barrier (BBB) integrity. Clinically, evidence levels remain uneven: probiotics/bifidobiotics have demonstrated improvements in inflammation and certain cognitive domains in small randomized controlled trials (RCTs); FMT has only been supported by case reports in human AD; modified ketogenic diets have shown correlations with cerebrospinal fluid (CSF) biomarkers; molecules such as GV-971 provide proof-of-concept for microbiota-targeted strategies but require broader independent validation. Overall, gut microbiota research in AD has entered a new phase, with animal and human studies indicating that dysbiosis can drive AD pathology through multiple pathways including immune, metabolic, and barrier dysfunction, though clinical intervention evidence remains inconsistent and requires further validation.

13 November 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
JWJiahui Wang
Jiahui Wang
PDPengcheng Duan
Pengcheng Duan
JDJiaxing D ou
Jiaxing D ou
SCShihan Chen
Shihan Chen
FXFeng Xue
Feng Xue
Alzheimer’s disease (AD) is no longer viewed simply as a proteinopathy driven by amyloid-β (Aβ) and tau. It also involves neuroimmune dysregulation, blood-brain barrier (BBB) and neurovascular unit (NVU) dysfunction, gut-brain axis perturbation, and peripheral metabolic imbalance. Dietary lipids are biologically distinct molecules that can influence these systems through membrane remodeling, lipid-mediator generation, receptor signaling, metabolic support, and central-peripheral crosstalk. Clinical studies of n-3 polyunsaturated fatty acids (PUFAs) and related lipid interventions have nevertheless produced inconsistent or negative results, which may reflect both genuinely limited efficacy in some settings and heterogeneity in lipid species, disease stage, formulation, exposure, and host background. We therefore place the proposed 4D framework within a broader systems-physiology concept of allostatic integrity: the capacity of interacting neural, glial, vascular, immune, and metabolic systems to adapt to repeated perturbations and return toward functional stability. We further use “biological memory” as an operational concept for persistent molecular and cellular state changes—such as epigenetic, metabolic, lipidomic, and glial-state remodeling—that can alter responses to subsequent challenges. The 4D framework comprises Disease stage, Dominant driver pathway, Delivery and formulation, and Data-guided stratification. It is intended as a hypothesis-generating research framework for trial design and stratification, not as a validated clinical algorithm. The 4D framework has not yet been prospectively validated, and its prospective utility remains to be tested.